Melina Arnold1, Mathieu Laversanne1, Linda Morris Brown2, Susan S Devesa3, Freddie Bray1. 1. Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France. 2. RTI International, Environmental and Health Sciences Unit, Biostatistics and Epidemiology Division, Rockville, Maryland, USA. 3. National Cancer Institute, Division of Cancer Epidemiology and Genetics, Biostatistics Branch, Bethesda, Maryland, USA.
Abstract
OBJECTIVES: Rapid increases in the incidence of esophageal adenocarcinoma (EAC) in high-income countries in the past decades have raised public health concerns. This study is the first to predict the future burden of esophageal cancer by histological subtype using international incidence data. METHODS: Data on esophageal cancer incidence by year of diagnosis, sex, histology, and age group were extracted from 42 registries in 12 countries included in the last three volumes (VIII-X) of Cancer Incidence in Five Continents, contributing at least 15 years of consecutive data. Numbers of new cases and incidence rates were predicted up to 2030 by fitting and extrapolating age-period-cohort models; the differential impact of demographic vs. risk changes on future cases were examined. RESULTS: The number of new AC cases is expected to increase rapidly 2005-2030 in all studied countries as a combined result of increasing risk and changing demographics. In contrast, the incidence of esophageal squamous cell carcinoma (ESCC) is predicted to continue decreasing in most countries. By 2030, 1 in 100 men in the Netherlands and the United Kingdom are predicted to be diagnosed with EAC during their lifetime. CONCLUSIONS: The burden from EAC is expected to rise dramatically across high-income countries and has already or will surpass ESCC incidence in the coming years, especially among men. Notwithstanding the inherent uncertainties in trend-based predictions and in subtype misclassification, these findings highlight an ongoing transition in the epidemiology of esophageal cancer that is highly relevant to future cancer control planning and clinical practice.
OBJECTIVES: Rapid increases in the incidence of esophageal adenocarcinoma (EAC) in high-income countries in the past decades have raised public health concerns. This study is the first to predict the future burden of esophageal cancer by histological subtype using international incidence data. METHODS: Data on esophageal cancer incidence by year of diagnosis, sex, histology, and age group were extracted from 42 registries in 12 countries included in the last three volumes (VIII-X) of Cancer Incidence in Five Continents, contributing at least 15 years of consecutive data. Numbers of new cases and incidence rates were predicted up to 2030 by fitting and extrapolating age-period-cohort models; the differential impact of demographic vs. risk changes on future cases were examined. RESULTS: The number of new AC cases is expected to increase rapidly 2005-2030 in all studied countries as a combined result of increasing risk and changing demographics. In contrast, the incidence of esophageal squamous cell carcinoma (ESCC) is predicted to continue decreasing in most countries. By 2030, 1 in 100 men in the Netherlands and the United Kingdom are predicted to be diagnosed with EAC during their lifetime. CONCLUSIONS: The burden from EAC is expected to rise dramatically across high-income countries and has already or will surpass ESCC incidence in the coming years, especially among men. Notwithstanding the inherent uncertainties in trend-based predictions and in subtype misclassification, these findings highlight an ongoing transition in the epidemiology of esophageal cancer that is highly relevant to future cancer control planning and clinical practice.
Authors: Annika Steffen; Matthias B Schulze; Tobias Pischon; Thomas Dietrich; Esther Molina; Maria-Dolores Chirlaque; Aurelio Barricarte; Pilar Amiano; J Ramón Quirós; Rosario Tumino; Amalia Mattiello; Domenico Palli; Paolo Vineis; Claudia Agnoli; Gesthimani Misirli; Paolo Boffetta; Rudolf Kaaks; Sabine Rohrmann; H Bas Bueno-de-Mesquita; Petra H M Peeters; Anne M May; Elizabeth A Spencer; Naomi E Allen; Sheila Bingham; Anne Tjønneland; Jytte Halkjaer; Kim Overvad; Jakob Stegger; Jonas Manjer; Björn Lindkvist; Göran Hallmanns; Roger Stenling; Eiliv Lund; Elio Riboli; Carlos A Gonzalez; Heiner Boeing Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-06-30 Impact factor: 4.254
Authors: Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen Journal: N Engl J Med Date: 2011-10-13 Impact factor: 91.245
Authors: Gina D Tran; Xiu-Di Sun; Christian C Abnet; Jin-Hu Fan; Sanford M Dawsey; Zhi-Wei Dong; Steven D Mark; You-Lin Qiao; Philip R Taylor Journal: Int J Cancer Date: 2005-01-20 Impact factor: 7.396
Authors: Mohammad H Derakhshan; Melina Arnold; David H Brewster; James J Going; David R Mitchell; David Forman; Kenneth E L McColl Journal: Am J Gastroenterol Date: 2016-01-12 Impact factor: 10.864
Authors: Rebecca C Fitzgerald; Massimiliano di Pietro; Krish Ragunath; Yeng Ang; Jin-Yong Kang; Peter Watson; Nigel Trudgill; Praful Patel; Philip V Kaye; Scott Sanders; Maria O'Donovan; Elizabeth Bird-Lieberman; Pradeep Bhandari; Janusz A Jankowski; Stephen Attwood; Simon L Parsons; Duncan Loft; Jesper Lagergren; Paul Moayyedi; Georgios Lyratzopoulos; John de Caestecker Journal: Gut Date: 2013-10-28 Impact factor: 23.059
Authors: Francisco Schlottmann; Charles Gaber; Paula D Strassle; Fernando A M Herbella; Daniela Molena; Marco G Patti Journal: Dis Esophagus Date: 2020-03-05 Impact factor: 3.429
Authors: Patrick Sven Plum; Dita Ulase; Elfriede Bollschweiler; Seung-Hun Chon; Felix Berlth; Thomas Zander; Hakan Alakus; Arnulf H Hölscher; Christiane J Bruns; Simon Schallenberg; Alexander Quaas; Heike Loeser Journal: J Cancer Res Clin Oncol Date: 2018-07-04 Impact factor: 4.553